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ABSTRACT
It has recently been shown that vascular endothelial
growth factor (VEGF) enhances vascular permeability
and that mast cells produce VEGF, suggesting the
involvement of VEGF in allergic diseases. In the present
study we quantitatively analyzed VEGF in the nasal
lavage fluid of patients with nasal allergy. We performed
nasal antigen challenge with Japanese cedar pollen
antigen in 10 healthy adult volunteers and in 10 cedar
pollen IgE-positive patients with nasal allergy. In all
patients with nasal allergy, VEGF and histamine levels in
the nasal lavage fluid reached a peak 30 min after
antigen challenge, then returned to prechallenge values
2 h after antigen challenge. In these patients, the hista-
mine level increased three-fold, while the VEGF level
increased 10-fold. However, in all healthy adult volun-
teers, VEGF and histamine levels did not increase. A
stronger correlation was noted between the ratio of
decreased nasal cavity volume and the ratio of increased
VEGF levels (R = 0.823; P < 0.001) than between the
ratio of nasal cavity volume and the ratio of increased
histamine levels (R = 0.660; P < 0.01). These results
suggest that VEGF may contribute to the pathogenesis of
nasal obstruction in the early phase of nasal allergy as a
new factor involved in increasing vascular permeability.
Key words: mast cells, nasal allergy, nasal antigen
challenge test, nasal obstruction, vascular endothelial
growth factor, vascular permeability.
INTRODUCTION
Patients with nasal allergy, a type I allergic disease,
present with major symptoms of sneezing, increased
nasal secretion and nasal obstruction. Type I allergy is
characterized by anaphylactic reactions caused by the
release of chemical mediators from mast cells induced by
IgE-antigen crosslinkage. Nasal obstruction is the most
significant of the three major symptoms because it is often
associated with mouth breathing, snoring, xerostomia
and sleep apnea syndrome. A decrease in the nasal
cavity volume is caused by vasodilatation and extra-
vascular leakage of plasma components. To investigate
the pathogenesis of nasal allergy, we evaluated the
chemical mediators in nasal lavage fluid after a single
antigen challenge.1,2
A growth factor with a regulatory role in angiogenesis
was found and termed vascular permeability factor (VPF)
by Senger et al.3 It has also been referred to as vas-
cular endothelial growth factor (VEGF) by Ferrara et al.4
Based on the difference in splicing, four types of VEGF
(VEGF121, VEGF165, VEGF189 and VEGF206) have been
detected.5 In an experimental study using guinea pigs,
VEGF increased vascular permeability when injected sub-
cutaneously. In the field of clinical medicine, VEGF has
been reported to participate in angiogenesis in solid
tumors and diabetic eyes.6,7 Vascular endothelial growth
factor is also found in carcinomatous ascites produced by
increased vascular permeability8 and VEGF is released
from various cells, such as tumor cells, epithelial cells,
fibroblasts and platelets.9–12 A recent study has shown
that VEGF is also produced by mast cells.13 This finding
suggests that VEGF has an important role in type I aller-
gic disease.
In the present study, we quantitatively analyzed VEGF
in the nasal lavage fluid of patients with nasal allergy
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before and after nasal antigen challenge. The nasal
cavity volume was also measured to evaluate the partici-
pation of VEGF in the development of nasal obstruction,
the symptom closely related to vascular permeability.
METHODS
Subjects
A total of 10 Japanese cedar pollinosis patients (mean
age 34 years; range 26–34 years) including eight males
and two females, participated in the present study.
Inclusion criteria for Japanese cedar pollinosis patients
were clinical symptoms of nasal hypersensitivity during
the Japanese cedar pollen-scattering season (January)
and positive results in the radioallergosorbent test (RAST;
score > 2) for Japanese cedar pollen. Patients who tested
positive in the RAST for other pollen antigens were
included as subjects if they showed no nasal hyper-
sensitivity outside the Japanese cedar pollen-scattering
season. However, all patients testing positive for antigens
against house dust and mites were excluded from the
study. The nasal cavity was required to be free of septal
deviations, nasal spurs and nasal polyps. The control
subjects consisted of 10 healthy adult volunteers (mean
age 32 years; range 24–38), including six males and four
females without a past history of allergic disease. The
study was performed in midwinter, out of the pollen
season, to avoid natural provocation.1,2
Study schedule
An antigen challenge was performed using two pollen
disks (total four disks; each disk was saturated with 
250 mg protein nitrogen, 0.3 mg total nitrogen of Japan-
ese Cedar) that were placed on the inferior turbinate.
Nasal lavage was performed 15 min and immediately
before antigen challenge, as well as at 30 min and 2, 4, 8
and 10 h after antigen challenge. Before the study,
informed consent was obtained from each subject after
adequately explaining the objectives and procedures of
the present study.
Nasal lavage
With the patient in a sitting position with his/her head
hanging down, a nozzle connected by a tube to a syringe
was inserted into a nostril to close the opening tightly and
the nasal cavity was washed with 10 mL physiological
saline warmed at 37°C by reciprocating the piston of the
syringe 10 times on each side. Lavage fluid recovered
was measured, mixed thoroughly, filtered through a nylon
filter net (Nippon Rikagaku Kikai Co., Tokyo, Japan) to
remove mucin and then centrifuged for 20 min at 4°C 
at 400 g. Vascular endothelial growth factor contained
within the mucin was ignored. The supernatant was
stored at –80°C until assayed for mediator levels. Vas-
cular endothelial growth factor in the nasal fluid was
measured with ELISA using a human VEGF immunoassay
(R&D Systems, Minneapolis, MN, USA; detection limit 
15.6 pg/mL). The kit used can detect two of the four
VEGF isoforms, namely VEGF121 and VEGF165. Histamine
was also measured by radioimmunoassay (RIA) using a
histamine RIA kit (Eiken Chemical, Tokyo, Japan; detec-
tion limit 0.11 ng/mL).
Nasal cavity volume measured by acoustic
rhinometry
Acoustic rhinometry is a method used for measuring the
area and length of the nasal cavity by acoustic reflection
for quantitative determination of nasal cavity geometry.14
An A1 acoustic rhinometer (‘GM’ Instruments Ltd, London,
UK) was used to determine nasal cavity volume. A range
of 8.5–10.5 cm3 from the wave tube of the acoustic 
rhinometer (1.5–3.5 cm3 from the tip of the nosepiece)
was used to determine the volume of the nasal cavity.
After patients had blown their noses, nosepieces were
closely attached to both the left and right nostrils and the
volume of the nasal cavity was measured and then
recorded on a computer. The percentage change in
nasal cavity volume (%) was determined by the formula:
(post-challenge nasal cavity volume/(post-challenge nasal
cavity volume – prechallenge nasal cavity volume)) · 100.
Statistical analysis
Results are expressed as the mean ± SEM. Comparisons
within groups were made using the Wilcoxon signed-rank
test for paired comparisons. Correlations were determined
using Spearman’s rank method (rank correlation coeffi-
cient). The statistical tests were performed on Macintosh
computers (Apple Computers, Cupertino, CA, USA) using
Statview software (Abacus Concepts, Berkeley, CA, USA). 
P < 0.05 was considered statistically significant.
RESULTS
In all patients with nasal allergy, VEGF levels in nasal
lavage fluid reached maximum values 30 min after
184 T YAMASHITA ET AL.
antigen challenge and returned to their prechallenge
values 2 h after nasal antigen challenge. As shown in 
Fig. 1, the VEGF level in the patient group was 65.6 ±
10.0 pg/mL before antigen challenge and increased to
581 ± 85 pg/mL 30 min after antigen challenge. How-
ever, in the control group, no significant differences were
noted in VEGF levels before and after antigen challenge
(58.6 ± 15.6 and 67.9 ± 30.0 pg/mL, respectively).
The histamine level in the patient group increased from
1.4 ± 0.6 ng/mL before antigen challenge to 4.0 ±
0.5 ng/mL 30 min after antigen challenge. In the control
group, no significant differences were noted between
before and 30 min after antigen challenge (0.9 ± 0.1
ng/mL and 1.1 ± 0.3 ng/mL, respectively; Fig. 1). Com-
pared with levels before antigen challenge, the histamine
level increased three-fold after antigen challenge in each
patient, while the VEGF level increased 10-fold.
As shown in Fig. 2, the nasal cavity volume before
antigen challenge was 3.1 ± 0.3 cm3, then it reached its
minimum value of 2.0 ± 0.3 cm3 30 min after antigen
challenge (P < 0.01). In the hours after challenge, a
complex pattern of reactions was observed in the allergy
group. The pooled data from all allergy patients showed
a slight decrease in nasal cavity volume; however, the
changes were not statistically significant. In the control
group, no significant differences were noted before and
after antigen challenge.
The correlation between the ratio of nasal cavity
volume decrease and the ratio of VEGF increase 
(R = 0.823; P < 0.001) was stronger than that between
the ratio of nasal cavity volume and the ratio of increased
histamine levels (R = 0.660; P < 0.01; Fig. 3).
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Fig. 1 Mediator levels in nasal lavage fluid after antigen
challenge. Antigen challenge was performed using two pollen
disks. Nasal lavage was performed 15 min and immediately
before antigen challenge, as well as at 30 min and 2, 4, 8 
and 10 h after antigen challenge. Data are the mean ± SEM 
(n = 10). (a) Vascular endothelial growth factor (VEGF). In
patients with nasal allergy (d), significant increases occurred
immediately after antigen challenge in the first 30 min, with no
differences in levels at later hours. However, in the control
group (j), no significant difference were observed before and
after antigen challenge. (b) Histamine. In patients with nasal
allergy (d), significant increases occurred immediately after
antigen challenge in the first 30 min, with no significant differ-
ences in histamine levels at later time points. However, in the
control group (j), no significant differences were observed
before and after antigen challenge.
Fig. 2 Changes in nasal cavity volume before and after
antigen challenge. A range of 8.5–10.5 cm3 from the wave
tube of the acoustic rhinometer (1.5–3.5 cm3 from the tip of the
nosepiece) was used to determine nasal cavity volume. Data
are the mean ± SEM (n = 10). In patients with nasal allergy
(d), nasal cavity volume significantly decreased immediately
after antigen challenge in the first 30 min. Although some
patients showed a decrease in nasal cavity volume at later time
points, the pooled data did not reach statistical significance. In
the control group (· ), no significant changes were observed
before and after antigen challenge.
DISCUSSION
Vascular endothelial growth factor was discovered as a
growth factor that specifically acted on vascular endo-
thelial cells.3,4 It was also found that VEGF was able to
enhance vascular permeability. Clinically, it has been
reported6,7,15 that VEGF participates in several conditions
caused by abnormal angiogenesis and increased vascu-
lar permeability, such as tumor growth and diabetic
retinopathy. We have confirmed the presence of VEGF in
the fluid of thyroid cysts, in the intra-ocular fluid of
patients with diabetic retinopathy and in the peripheral
blood of patients with solid tumors.6,7,15 Recently, knock-
out mice for VEGF and the VEGF receptor gene were
developed to investigate the role of VEGF in angio-
genesis during the early developmental stage.16–18 A
neutralizing antibody to VEGF was found to have both
antitumor and antimetastatic effects and, thus, is expected
to be useful as an anticancer drug.18,19 Gene therapy
based on the physiologic activities of VEGF is now under
investigation: namely, transduction of a VEGF165 expres-
sion vector in patients with arteriosclerosis obliterans and
intramuscular injections of VEGF cDNA plasmids in
patients with chronic arterial obstruction in the lower
extremities.20–22
It has recently been reported that VEGF is expressed 
in keratinosytes during delayed type allergic reactions.23
However, VEGF has not been reported to directly par-
ticipate in the development of allergy. Boesiger et al.13
suggested the possibility of VEGF participating in the
pathogenesis of allergic disease because VEGF was pro-
duced by mast cells in an in vitro experiment.
To confirm the presence of VEGF in the nasal cavity
with allergic reactions, we measured VEGF and hista-
mine levels in nasal lavage fluid after a single antigen
challenge test in patients with nasal allergy. Changes in
nasal cavity volume were also measured to examine the
correlation between nasal obstruction with VEGF and/or
histamine levels. The present study, where the time-
course of changes in chemical mediators can be detected,
is considered to be suitable for investigating the patho-
genesis of nasal allergy.
On the basis of results of the present study, the VEGF
level in nasal lavage fluid increased after nasal antigen
challenge exclusively in the patient group. The levels of
VEGF 30min after antigen challenge increased approxi-
mately 10-fold compared with levels before antigen
challenge. The levels of VEGF in nasal fluid 30 min after
antigen challenge were almost at the same level as in the
intra-ocular fluid in diabetic eyes with increased vascular
permeability,7 although a direct comparison between dif-
ferent organs is difficult to make.
Nasal obstruction is, in part, caused by a decrease in
nasal cavity volume secondary to interstitial edema due
to extravascular leakage of plasma components. Muco-
sal edema in the nasal cavity is refractory to anti-
histaminic drugs (first generation histamine H1 receptor
antagonists) in most cases, although it is responsive to
topical steroids.24,25 This is explained by the decrease in
the number of mast cells in the nasal mucosa. Unknown
factors, other than histamine, released from mast cells
may play a role in the development of nasal obstruction
because antihistaminic drugs are ineffective in treating
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Fig. 3 Correlation between the ratio of nasal cavity volume
decrease and the ratio of mediator increase. The correlation
between the ratio of nasal cavity volume decrease and (a) the
ratio of vascular endothelial growth factor (VEGF) increase was
greater than that between the ratio of nasal cavity volume
decrease and (b) the ratio of histamine (HA) increase. For 
(a): r = 0.823, P < 0.001. For (b): r = 0.660, P < 0.01.
the symptoms, although it has been reported that mucus
edema was reduced after medication with mediator
release inhibitors in patients with nasal allergy.26 In addi-
tion, transient edema is a side effect of gene therapy with
VEGF.21,22 Therefore, VEGF may cause edema in the
nasal mucosa.
In the present study, the histamine level was approxi-
mately seven-fold greater than the VEGF level at the peak
time after antigen challenge in patients with nasal allergy.
However, it has also been reported that the role of VEGF
in the enhancement of vascular permeability is 50 000-
fold stronger than that of histamine in vitro.27 With regard
to inducing increased vascular permeability, VEGF may
be more active than histamine, although the metabolism
and the density and distribution of the receptors should
be considered. Moreover, the correlation between the
ratio of decreased nasal cavity volume and the ratio of
increased VEGF levels was greater than that between the
ratio of decreased nasal cavity volume and the ratio of
increased histamine levels.
These results suggest that VEGF is a new factor in the
development of nasal obstruction in the early phase. Both
VEGF and histamine levels increased in a similar manner
and reached their peak values 30 min after antigen chal-
lenge. Based on the fact that mast cells produce VEGF, it
is certain that VEGF, as well as histamine, in nasal lavage
fluid is derived from mast cells in the nasal mucosa.
Because the kinetics of VEGF level are similar to those of
histamine, there is a possibility that histamine induces
VEGF release from mast cells. However, to our knowl-
edge, there is no report regarding the effect of histamine
on VEGF production or on mast cell degranulation. In
fact, in a preliminary study using cultured mast cells, 
we were not able to observe an increase in VEGF levels
from mast cells when they were cultured with histamine 
(T Yamashita et al., unpubl. obs., 1999).
Various mediators, including arachidonic acid meta-
bolites (such as platelet-activating factor and leukotrienes)
and eosinophil granule proteins, have already been
reported to participate in the pathogenesis of late phase
response.1,28 Considering the fact that neither histamine
nor VEGF levels were increased in the late phase, they
are unlikely to contribute to the nasal swelling in the late
phase response.
Consequently, our present study revealed the presence
of VEGF in nasal lavage fluid. The results also suggest
that VEGF, also known as a vascular permeability factor,
possesses a close relationship with the development of
nasal obstruction. In the future, VEGF may be one of the
targets of therapy for nasal obstruction in patients with
nasal allergy.
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